New combo therapy aims to boost immune response in hard-to-treat lung cancer
NCT ID NCT07027514
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 28 times
Summary
This early-stage study tests a new drug (tolododekin alfa) combined with an existing immunotherapy for people with advanced non-small cell lung cancer. The goal is to see if the combination can shrink tumors or slow disease progression. About 60 participants will join, including those who have already tried standard treatments and those who have not yet been treated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barbara Ann Karmanos Cancer Hospital
RECRUITINGDetroit, Michigan, 48201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Community Health Network
RECRUITINGIndianapolis, Indiana, 46256, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
FirstHealth of the Carolinas
RECRUITINGPinehurst, North Carolina, 28374, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.